Mr. Ron Nagar reports

TEMPRAMED ANNOUNCES GRANTED INDIAN DESIGN PATENT FOR VIVI CAP SMART PRODUCT

Tempramed Technologies Ltd.'s Indian design application No. 417105-001 for the Vivi Cap Smart has now been formally granted by the Indian Patent Office.

Highlights:

• Granted patent covers the design of Vivi Cap Smart across major international, growing market;
• Strengthens the company's intellectual property position in one of the world's largest health care and consumer markets;
• Supports commercialization strategy and strategic discussions with appliance manufacturers;
• Design term extends through May 16, 2039;
• Company enters into financing arrangement to support inventory build for growing portfolio.

The design protects key design aspects of the company's Vivi Cap Smart device, which has already begun sales globally. Vivi Cap Smart builds on the success of the original Vivi Cap, which provides continuous protection for insulin and GLP-1 pens against temperature fluctuations without the need for user intervention or maintenance. Insulin and GLP-1, if exposed to temperatures outside of room temperature, can weaken or damage the medicine, causing suboptimal treatment. Using its proprietary, space-grade technology, Tempramed's product portfolio protects and prevents insulin and other life-saving medication from being compromised, which reduces wasted medication, as well as negative patient outcomes.

Vivi Cap Smart adds an integrated digital layer designed to support daily medication management by enabling users to track injection timing automatically and maintain an accurate log of insulin usage through an optional connected mobile application. These important data can be stored, tracked and shared with health care providers to ensure an integrated treatment plan.

Without limiting the scope of the design, it shows elements of Tempramed's proprietary thermal-insulation and smart-monitoring architecture, such as:

• Continuous temperature protection around the medication;
• Portable, durable and easy handling;
• Onboard timer and electronics for supporting adherence and remote monitoring.

These capabilities position Vivi Cap Smart at the intersection of home health care, digital health and connected medical devices, supporting Tempramed's strategy to expand beyond single-injection protection into scalable, multiformat medication management solutions.

"India represents one of the world's most significant diabetes markets, with approximately 89.8 million adults living with diabetes today and that number projected to reach 156.7 million by 2050," said Ron Nagar, chief executive officer of Tempramed. "The grant of our Indian design protection is an important milestone in Tempramed's global IP [intellectual property] strategy and strengthens our ability to commercialize Vivi Cap Smart in a market where millions of patients depend on temperature-sensitive injectable medications every day. As Tempramed expands its global footprint across North America, Europe, Asia and other high-growth health care markets, protecting our core innovations is essential to building long-term competitive advantage, supporting partner confidence and creating durable shareholder value. Strong patent and design protection allow us to defend our technology, accelerate commercialization and continue advancing our mission to become a global leader in temperature-controlled medication management."

The Indian design grant builds on Tempramed's growing portfolio of granted patents and designs across key international jurisdictions, including recent grants in other major international markets. Together, these milestones support the company's multiyear strategy to scale globally, introduce new product categories, and expand partnerships across health care systems, pharmacy networks and medical device ecosystems.

With a strong foundation of patented, FDA-registered (U.S. Food and Drug Administration) technologies and increasing validation from clinicians and distribution partners around the world, including validation of its return on investment (ROI) model for insurance payers as verified by hundreds of clinicians recommending Tempramed's Vivi Cap to patients. For more information on the ROI validation of Vivi Cap, please refer to the company's press release dated March 11, 2026. Tempramed continues to advance its mission of ensuring the safety, efficacy and accessibility of life-saving medications.

Royalty purchase agreement

The company also announces it has renewed its royalty purchase agreement (RPA) dated May 11, 2026, with an arm's-length purchaser. The renewed RPA supersedes the prior royalty purchase agreement between the company and the purchaser dated Oct. 6, 2023 (as amended), although the terms of the renewed RPA remain substantially similar to those of the original agreement, which are disclosed in the company's audited consolidated financial statements for the financial year ended Dec. 31, 2025.

Under the renewed RPA, the purchaser has agreed to pay the company $500,000 (U.S.) (delivered as a net cash payment of approximately $365,000 (U.S.) after settlement of the balance outstanding under the prior agreement) in exchange for the right to receive 10 per cent of the company's group revenues, together with a recurring monthly service charge and a one-time administrative charge. The company's obligations under the renewed RPA are secured by a continuing security interest over substantially all of the company's assets. The renewed RPA also contains negative covenants restricting the company's ability to incur additional indebtedness above $1-million (U.S.), sell assets outside the ordinary course, and other customary covenants and default provisions. The company may repay all amounts outstanding under the renewed RPA any time after Aug. 11, 2026, subject to providing the purchaser 30 days of notice.

The company will use the funds from the renewed RPA to support its inventory.

Further details regarding the prior royalty purchase agreement are disclosed in Note 7(b) to the company's audited consolidated financial statements for the year ended Dec. 31, 2025, which are available under the company's profile on SEDAR+.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered, thermal-insulation devices that work 24 hours a day, seven days a week without batteries or external power. With a product line already in market, including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed will continue to expand globally, offering a solution for medication protection and adherence.

We seek Safe Harbor.